Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.52 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9325738 | 1.00 | CA1 (0.53) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL20478665 | 0.91 | PIN1 (0.52) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1847083 | 0.91 | PIN1 (0.52) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL12662601 | 0.88 | CA1 (0.53) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5520518 | 0.87 | CA1 (0.55) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL20478894 | 0.87 | CA1 (0.52) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5848209 | 0.87 | CA1 (0.55) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5848210 | 0.87 | CA1 (0.55) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5848207 | 0.87 | CA1 (0.55) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL8807888 | 0.85 | FFAR1 (0.47) | TAS1R3TAS1R1TAS1R2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| EP-1318140-B9 | NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-05-21 | — | — | EP | disclosed |
| US-8198454-B2 | Amide derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-12 | — | — | US | disclosed |
| EP-1318140-B1 | NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-05-18 | — | — | EP | disclosed |
| US-7855297-B2 | Amide derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20100041656-A1 | Novel amide derivatives and medicinal use thereof | NAKAMURA MITSUBARU | 2010-02-18 | — | — | US | disclosed |
| WO-2009104058-A1 | TRITIUM RADIOLABELING OF [3H]-1-CYCLOHEXYL-4-[3-(5-METHOXY-1,2, 3,4,-TETRAHYDRONAPHTHALEN-1-YL)-N-PROPYL]PIPERAZINE ([3H]-PB28), AS A POTENT SIGMA-2 RECEPTOR LIGAND | UNIVERSITA' DEGLI STUDI DI BARI (IT) | 2009-08-27 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
| US-20040138223-A1 | Novel amide derivatives and medicinal use thereof ugs | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1318140-A1 | NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF UGS | Mitsubishi Pharma Corporation (JP) | 2003-06-11 | — | — | EP | disclosed |
| US-5140040-A | Alpha-2-adrenergic receptor antagonist; glaucoma; congestive heart failure; hypotensive agents; headaches; metabolic disorders (diabetes, obesity) | ABBOTT LABORATORIES (US) | 1992-08-18 | — | — | US | disclosed |
| US-5128362-A | Antidepressant, antiglaucoma | ABBOTT LABORATORIES (US) | 1992-07-07 | — | — | US | disclosed |
| US-5086074-A | Selective adrenergic receptor antagonists | ABBOTT LABORATORIES (US) | 1992-02-04 | — | — | US | disclosed |
| EP-0395734-A4 | 1-AMINOMETHYL-1,2,3,4-TETRAHYDRONAPHTHALENES | — | 1991-01-02 | — | — | EP | disclosed |
| EP-0395734-A1 | 1-AMINOMETHYL-1,2,3,4-TETRAHYDRONAPHTHALENES | ABBOTT LABORATORIES (US) | 1990-11-07 | — | — | EP | disclosed |
| EP-0325963-A1 | 1-Aminomethyl-1,2,3,4-tetrahydronaphthalenes and -indanes | ABBOTT LABORATORIES (US) | 1989-08-02 | — | — | EP | disclosed |
| WO-1989006645-A1 | 1-AMINOMETHYL-1,2,3,4-TETRAHYDRONAPHTHALENES | ABBOTT LABORATORIES (US) | 1989-07-27 | — | — | WO | disclosed |
| US-4530919-A | A 1,2,3,4-tetrahydronaphthalene carboxylic acid | PFIZER INC. (US) | 1985-07-23 | — | — | US | disclosed |
| US-4374148-A | HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1983-02-15 | — | — | US | disclosed |
| US-4305955-A | ORAL HYPOGLYCEMIC AGENTS, CHROMAN-4-CARBOXYLIC ACID OR THIOCHROMAN-4-CARBOXYLIC ACID | PFIZER INC. (US) | 1981-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | CA1 1947/4885CA2 1916/4885TAS1R3 380/4885 |
| US-20100041656-A1 | Novel amide derivatives and medicinal use thereof | C5AR1, C5AR2, C3AR1 | CA1 1182/4885CA2 3196/4885TAS1R3 2626/4885 |
| US-20040138223-A1 | Novel amide derivatives and medicinal use thereof ugs | C5AR1, C5AR2, C1S | CA1 1620/4885CA2 3991/4885TAS1R3 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.